Stakeholder Views on Participant Selection for First-in-Human Trials in Cancer Nanomedicine | Zendy

Priya Satalkar | Zendy; Bernice S. Elger | Zendy; David Shaw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Stakeholder Views on Participant Selection for First-in-Human Trials in Cancer Nanomedicine

Author(s) -

Priya Satalkar,

Bernice S. Elger,

David Shaw

Publication year - 2016

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.23.3214

Subject(s) - medicine , clinical trial , alternative medicine , generalizability theory , thematic analysis , research ethics , disease , family medicine , qualitative research , psychology , psychiatry , pathology , developmental psychology , social science , sociology

Participant selection for first-in-human (fih) trials involves complex decisions. The trial design makes it unlikely that participants will receive clinically relevant therapeutic benefit, but they are likely to experience risks of various magnitudes and types. The aim of the present paper was to describe and discuss the views of investigators and ethics committee members about the choice of trial participants for fih trials in cancer nanomedicine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research